Skiplink Navigation

Main Features

Roche cancer drug gets grim prognosis

Avastin, the top drug of Swiss pharmaceutical company Roche, may lose its approval for treating breast cancer in the United States.

As the world’s best-selling cancer medicine, Avastin has been approved for treating a variety of cancers. However, it failed to extend lives in four trials involving breast cancer patients.

"Given the number of serious and life-threatening side effects, the FDA does not believe there is a favourable risk-to-benefit ratio," Dr Richard Pazdur, the US Food and Drug Administration's head of cancer drugs, told reporters on Thursday.

Some side effects include holes in the stomach and intestines plus bleeding and blood clots.

Roche says that these problems occurred in less than four per cent of patients in the trials. The Basel-based company plans to request a hearing to contest the US decision. In the meantime, Avastin will retain its FDA approval.

In the wake of the news, analysts estimate that the Roche Group could lose as much as $1 billion (SFr0.97 billion) of its $6 billion in annual sales. and agencies


Neuer Inhalt

Horizontal Line

Survey Swiss Abroad

Survey: Keyboard and Hand close-up

Dear Swiss Abroad, tell us what you think

Survey Swiss Abroad

subscription form

Form for signing up for free newsletter.

Sign up for our free newsletters and get the top stories delivered to your inbox.

Click here to see more newsletters